Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
Arrowhead Pharmaceuticals (ARWR) will present clinical data at the American Heart Association Scientific Sessions 2026. Key presentations include results from a Phase 1/2a study of ARO-DIMER-PA for mixed hyperlipidemia, a pooled analysis of plozasiran in severe hypertriglyceridemia (sHTG), and long-term data on plozasiran in familial chylomicronemia syndrome (FCS). Plozasiran is under review for sHTG and approved for FCS in several regions.
How this was made
The 30-second read
Why it matters
The disclosures represent the first public read‑out of these programs, providing fresh material for valuation models.
Market read
First‑time trial data release; potential catalyst for ARWR and related RNAi stocks.
What to watch
Regulatory timelines and competition from other lipid‑lowering agents may temper upside.
Background
Arrowhead Pharmaceuticals announced upcoming presentations of its dual‑functional RNAi candidate ARO‑DIMER‑PA and pooled Phase 3 data for plozasiran at the American Heart Association Scientific Sessions.
Ticker impact
Arrowhead Pharmaceuticals will present first-in-human dual‑RNAi data for ARO‑DIMER‑PA and pooled Phase 3 results for plozasiran at the AHA Scientific Sessions on Nov 7.
likely upside as market prices in the new clinical data
First‑time disclosure of early‑stage data; biotech stocks typically react strongly to trial readouts.
Market effects
Could boost the broader lipid‑lowering RNAi/siRNA therapeutic sector if data are positive.
U.S. biotech market may see modest gains; European peers in RNAi may be affected.
Limited to investors focused on biotech and lipid‑lowering therapies.
Counterpoint
If data are modest, the stock could face disappointment and short‑term pressure.
Key entities
- companyArrowhead Pharmaceuticals
US‑listed biotech developing RNAi therapeutics for lipid disorders.
